Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multi-center Study to Evaluate theSafety and Efficacy of Selinexor Combined With Chemotherapy orTislelizumab in Relapsed or Refractory Mature T and NK Cell Lymphoma

NCT04425070 is registered in ClinicalTrials.gov with Antengene Corporation as lead sponsor.

NCT NCT04425070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04425070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multi-center Study to Evaluate theSafety and Efficacy of Selinexor Combined With Chemotherapy orTislelizumab in Relapsed or Refractory Mature T and NK Cell Lymphoma
Lead sponsor
Antengene Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
August 18, 2020
Completion date
December 30, 2025
Enrollment
56 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

nk/t-cell lymphoma, peripheral t-cell lymphoma